Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Br J Dermatol, 2020.
Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group.
Read publication: Br J Dermatol
Related
Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe pso...
The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celeb...
Age and biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the Br...
Contact Us
Find Us
The University of Manchester
First Floor Bright Building
Manchester Science Park
Manchester
M15 6GZ
0 Comments